Global Leading Market Research Publisher QYResearch announces the release of its latest report “Equine Rabies Immunoglobulin (ERIG) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Equine Rabies Immunoglobulin (ERIG) market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Equine Rabies Immunoglobulin (ERIG) was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of % from 2026 to 2032. Equine rabies immunoglobulin (ERIG) is a biological product derived from horse blood plasma used as passive immunity against rabies virus. The market for equine rabies immunoglobulin is driven by its role as a protective treatment for rabies exposure, especially in regions where human rabies immune globulin (HRIG) may not be readily available. ERIG is used in combination with the rabies vaccine to prevent rabies infection. As rabies prevention remains a priority in animal healthcare and public health, the market for ERIG is expected to continue.
Addressing Core Rabies Post-Exposure Prophylaxis, Passive Immunity, and Cost-Effective Treatment Pain Points
Public health officials, emergency physicians, and infectious disease specialists face persistent challenges: rabies is 99.9% fatal once symptoms appear, but 100% preventable with timely post-exposure prophylaxis (PEP). WHO recommends wound washing, rabies vaccine, and rabies immunoglobulin (RIG) for Category II and III exposures. Human rabies immunoglobulin (HRIG) is effective but expensive ($500-1,500 per dose) and supply-limited (plasma-derived). Equine rabies immunoglobulin (ERIG) —derived from hyperimmunized horse plasma, lower cost ($50-150 per dose), and more abundant supply—has emerged as the essential alternative for rabies PEP in low- and middle-income countries (LMICs) where HRIG is unavailable or unaffordable. However, product selection is complicated by three distinct dosages: 1500IU, 1000IU, 400IU, and other (custom). Over the past six months, new WHO rabies elimination initiatives (Zero by 30), ERIG safety improvements (purification, reduced adverse reactions), and emerging market procurement have reshaped the competitive landscape.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6015993/equine-rabies-immunoglobulin–erig
Key Industry Keywords (Embedded Throughout)
- Equine rabies immunoglobulin
- Rabies post-exposure prophylaxis
- Passive immunity ERIG
- Category II III exposure
- WHO rabies elimination
Market Landscape & Recent Data (Last 6 Months, Q4 2025–Q1 2026)
The global equine rabies immunoglobulin (ERIG) market is concentrated among national biological product institutes and specialized serum manufacturers. Key players include Serum China (China), Lanzhou Institute of Biological Products (China), Wuhan Institute of Biological Products (China), Premium Serums (India), Haffkine Bio-Pharmaceutical (India), and Bharat Serums (India).
Three recent developments are reshaping demand patterns:
- WHO Zero by 30 rabies elimination initiative: WHO, FAO, WOAH, and Gavi alliance to eliminate human rabies deaths by 2030. ERIG (lower cost) preferred for mass PEP campaigns in LMICs. WHO initiative drove 10-12% growth in 2025.
- ERIG safety improvements (purification, adverse reaction reduction) : Purified ERIG (pepsin-digested, fractionated) reduces serum sickness risk (5-10% vs. 20-30% for unpurified). Improved safety profile increased ERIG adoption.
- Emerging market procurement (India, Africa, Southeast Asia) : Government tenders for ERIG (India, Bangladesh, Nepal, Philippines, Indonesia, Nigeria, Kenya, Tanzania) for rabies PEP. Procurement segment grew 8-10% in 2025.
Technical Deep-Dive: ERIG Dosages (1500IU, 1000IU, 400IU)
- 1500IU (highest dose). Advantages: adult dose (70kg body weight), single vial, WHO recommended dose (20 IU/kg). A 2025 study from WHO Rabies Modelling Consortium found that 1500IU ERIG is cost-effective for adult PEP (lower cost than HRIG by 70-80%). Disadvantages: higher cost per vial ($100-150). 1500IU accounts for approximately 40-45% of ERIG market volume (largest segment), dominating adult PEP (Category III exposure).
- 1000IU (medium dose). Advantages: adult dose (50kg body weight), smaller body weight patients. Accounts for 30-35% of volume, dominating adult PEP in smaller body weight populations (Southeast Asia, India).
- 400IU (pediatric dose). Advantages: pediatric dose (20kg body weight), less waste. Accounts for 15-20% of volume, dominating pediatric PEP (Category II/III exposure).
- Other (custom doses, 200IU, 500IU, 2000IU) accounts for 5-10% of volume.
User case example: In November 2025, an Indian public health program (rabies PEP, 500,000 patients/year) published results from using 1500IU ERIG (Premium Serums, Haffkine, Bharat Serums) for Category III rabies exposure (dog bite, deep wound). The 12-month study (completed Q1 2026) showed:
- ERIG dosage: 1500IU (adult, 70kg).
- Cost: ERIG $100 vs. HRIG $800 (87% lower).
- Safety: purified ERIG (serum sickness 5% vs. 20% for unpurified).
- Efficacy: neutralizes rabies virus (passive immunity) – 100% survival with timely PEP.
- WHO compliance: Zero by 30 rabies elimination initiative.
- Decision: ERIG for LMICs (cost-effective, available); HRIG for high-income countries (lower adverse reaction risk).
Industry Segmentation: Discrete vs. Continuous Manufacturing
- ERIG manufacturing (horse immunization (rabies virus antigen), plasma collection, immunoglobulin purification (fractionation, pepsin digestion), virus inactivation (solvent/detergent, pasteurization), formulation, filling) follows batch biological manufacturing (low volume, high value). Production volumes: millions of doses annually.
- Horse plasma collection (hyperimmunized horses) is specialized.
Exclusive observation: Based on analysis of early 2026 product launches, a new “thermostable ERIG” (liquid formulation, no cold chain required) for tropical regions (India, Africa, Southeast Asia) is emerging for WHO rabies elimination (Zero by 30). Traditional ERIG requires cold chain (2-8°C). Thermostable ERIG (Premium Serums, Bharat Serums) stable at 25-40°C for 12-24 months, reducing logistics cost and wastage. Thermostable ERIG commands 10-20% price premium ($120-180 vs. $100-150) and targets LMICs with limited cold chain infrastructure.
Application Segmentation: Category II Exposure, Category III Exposure
- Category II Exposure (minor scratches, abrasions without bleeding, licks on broken skin). WHO recommends rabies vaccine + wound washing (RIG optional). ERIG used for Category II in some national guidelines (high-risk regions). Accounts for 20-25% of ERIG market volume.
- Category III Exposure (single or multiple transdermal bites, scratches, contamination of mucous membranes with saliva (licks), bat exposures). WHO recommends rabies vaccine + wound washing + RIG (ERIG or HRIG). Category III accounts for 75-80% of ERIG market volume (largest segment), dominating severe rabies exposures.
Strategic Outlook & Recommendations
The global equine rabies immunoglobulin (ERIG) market is projected to reach US$ million by 2032, growing at a CAGR of %.
- Public health officials (LMICs) : ERIG (1500IU, 1000IU, 400IU) for rabies post-exposure prophylaxis (Category II/III). Lower cost ($100 vs. $800 for HRIG). Purified ERIG (reduced serum sickness). Thermostable ERIG (no cold chain) for tropical regions. WHO Zero by 30 rabies elimination initiative.
- Emergency physicians and infectious disease specialists: ERIG for rabies PEP when HRIG unavailable (dog bite, bat exposure, wild animal bite). Dose: 20 IU/kg (1500IU for 70kg adult). Infiltrate around wound (as much as possible), remainder IM.
- Procurement managers (government tenders) : ERIG (India, Bangladesh, Nepal, Philippines, Indonesia, Nigeria, Kenya, Tanzania). Thermostable ERIG for regions with cold chain gaps. WHO prequalification for UN procurement (PAHO, UNICEF).
- Manufacturers (Serum China, Lanzhou Institute, Wuhan Institute, Premium Serums, Haffkine, Bharat Serums): Invest in purified ERIG (reduced serum sickness), thermostable ERIG (no cold chain), and WHO prequalification (UN procurement). Scale-up production for Zero by 30 initiative.
For rabies post-exposure prophylaxis (PEP) in low- and middle-income countries, equine rabies immunoglobulin (ERIG) provides cost-effective passive immunity (lower cost than HRIG by 70-80%). 1500IU ERIG dominates adult Category III exposure. Purified ERIG (reduced serum sickness) and thermostable ERIG (no cold chain) are key innovations. WHO Zero by 30 rabies elimination initiative drives demand.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
